U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06850480) titled 'A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis' on Feb. 07.
Brief Summary: To evaluate the efficacy and safety of JP-1366 tablets and Nexium(R) (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
Study Start Date: Dec. 05, 2024
Study Type: INTERVENTIONAL
Condition:
Reflux Esophagitis (RE)
Intervention:
DRUG: JP-1366 simulation tablets
qd, last for 4-8 weeks
DRUG: Esomeprazole Magnesium (Nexium) simulation tablets
qd, last for 4-8 weeks
Recruitment Status: RECRUITING
Sponsor: Livzon Pharmaceutical Group Inc.
Published by HT Digital Co...